Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine whether ELND005 is effective in treating
symptoms of agitation and aggression in patients with Alzheimer's disease
Phase:
Phase 2
Details
Lead Sponsor:
OPKO Health, Inc. Transition Therapeutics Ireland Limited